Minerva Neurosciences Inc. (NERV) and Audentes Therapeutics Inc. (NASDAQ:BOLD) Comparison side by side

Minerva Neurosciences Inc. (NASDAQ:NERV) and Audentes Therapeutics Inc. (NASDAQ:BOLD), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Minerva Neurosciences Inc. N/A 0.00 36.81M -1.19 0.00
Audentes Therapeutics Inc. N/A 0.00 117.60M -2.72 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Minerva Neurosciences Inc. and Audentes Therapeutics Inc.


Table 2 shows Minerva Neurosciences Inc. and Audentes Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Minerva Neurosciences Inc. 0.00% -31.7% -22%
Audentes Therapeutics Inc. 0.00% -40.5% -37.5%


The Current Ratio and a Quick Ratio of Minerva Neurosciences Inc. are 26.2 and 26.2. Competitively, Audentes Therapeutics Inc. has 14.8 and 14.8 for Current and Quick Ratio. Minerva Neurosciences Inc.’s better ability to pay short and long-term obligations than Audentes Therapeutics Inc.

Institutional & Insider Ownership

Roughly 79.9% of Minerva Neurosciences Inc. shares are held by institutional investors while 91.7% of Audentes Therapeutics Inc. are owned by institutional investors. 0.1% are Minerva Neurosciences Inc.’s share held by insiders. Comparatively, insiders own roughly 0.9% of Audentes Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Minerva Neurosciences Inc. 0.51% -22.59% -18.46% -5.92% 41.96% 31.4%
Audentes Therapeutics Inc. -4.62% -3.76% -34.73% -40.11% -19.28% -25.38%

For the past year Minerva Neurosciences Inc. had bullish trend while Audentes Therapeutics Inc. had bearish trend.


Minerva Neurosciences Inc. beats Audentes Therapeutics Inc. on 6 of the 6 factors.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.